Literature DB >> 3203705

Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing.

A Lindholm1, S Henricsson, M Lind, R Dahlqvist.   

Abstract

We have measured total and unbound plasma concentrations of cyclosporin A in seven healthy men after single oral doses (12 mg per kg body weight) on two occasions at least two weeks apart. There was an up to two-fold intraindividual and a more than three-fold interindividual variation in the AUCs of both total and unbound drug. The intraindividual variability in the AUC of cyclosporin is similar to that of many other drugs and needs to be taken into account in the planning of pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203705     DOI: 10.1007/bf01046702

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Intraindividual variation in drug disposition.

Authors:  A P Alvares; A Kappas; J L Eiseman; K E Anderson; C B Pantuck; E J Pantuck; K C Hsiao; W A Garland; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

2.  Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects.

Authors:  J Grevel; E Nüesch; E Abisch; K Kutz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Semi-automated high-performance liquid chromatographic determination of cyclosporine A in whole blood using one-step sample purification and column-switching.

Authors:  G Hamilton; E Roth; E Wallisch; F Tichy
Journal:  J Chromatogr       Date:  1985-06-14

4.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

5.  A new method for measuring the free fraction of cyclosporin in plasma by equilibrium dialysis.

Authors:  S Henricsson
Journal:  J Pharm Pharmacol       Date:  1987-05       Impact factor: 3.765

6.  Cyclosporine monitoring in liver transplant patients.

Authors:  W Andrews; S Iwatsuki; B W Shaw; T E Starzl
Journal:  Transplantation       Date:  1985-03       Impact factor: 4.939

7.  Cyclosporine kinetics in renal transplantation.

Authors:  R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

8.  The effect of food on cyclosporine absorption.

Authors:  R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

9.  Lack of influence of an intensive antacid regimen on theophylline bioavailability.

Authors:  R C Reed; H J Schwartz
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

10.  Implications of intraindividual variability in bioavailability studies of furosemide.

Authors:  A Grahnén; M Hammarlund; T Lundqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  20 in total

1.  Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.

Authors:  M O Karlsson; A Lindberg-Freijs
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  Enhancement of the oral absorption of cyclosporin in man.

Authors:  J Drewe; R Meier; J Vonderscher; D Kiss; U Posanski; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.

Authors:  Mari Jiko; Ikuko Yano; Hiroko Wakasugi; Hideyuki Saito; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

4.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

5.  On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation.

Authors:  S Ohlman; A Lindholm; H Hägglund; J Säwe; B D Kahan
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

7.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  Preparation and evaluation of poly(ethylene glycol)-poly(lactide) micelles as nanocarriers for oral delivery of cyclosporine a.

Authors:  Yanhui Zhang; Xinru Li; Yanxia Zhou; Xiaoning Wang; Yating Fan; Yanqing Huang; Yan Liu
Journal:  Nanoscale Res Lett       Date:  2010-03-27       Impact factor: 4.703

9.  A study of the interaction between omeprazole and cyclosporine in renal transplant patients.

Authors:  I Blohmé; J P Idström; T Andersson
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 10.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.